Management of Patients with Advanced Prostate Cancer
Published Online: Tuesday, January 22, 2013
For High-Definition, ClickRaoul D. Concepcion, MD, begins the discussion by posing the question as to what sorts of models or protocols are being put into place to evaluate and manage patients with regards to sequencing different types of therapies (immunotherapy, oral therapy, cytotoxic chemotherapy).
Daniel R. Saltzstein, MD, says that a multidisciplinary approach works best for his practice where a radiation oncologist is involved with a medical oncologist. Though he can offer his patients clinical trials, few trials have actually been completed to determine appropriate drug combinations and sequencing.
Bryan Mehlhaff, MD, stresses that every community will have a slightly different setup, depending on what a urologist feels comfortable with. It remains important, Mehlhaff says, to keep patients in the loop and provide them with options every step of the way.
Though his practice has 20 physicians, Steve Dobbs, FACHE, has not looked into bringing a full-time medical oncologist in. As drugs are approved, urology as a business will have to adjust to reimbursement with regards to disease management and episodic care.
Concepcion wraps up the discussion by emphasizing the need to change practice models in urology to avoid marginalizing itself as reimbursement changes.
View More From This Discussion
Steve DobbsCEO, Urologic Associates of Oklahoma,
Bryan A. Mehlhaff, MDPrincipal Investigator, Division of Clinical Research, Oregon Urology Institute, Springfield, Oregon
Neal D. Shore, MDDirector, CPI, Carolina Urologic Research Center, Grand Strand Urology/Atlantic Urology Clinics, Myrtle Beach,
Daniel R. Saltzstein, MDMedical Director, Urology San Antonio Research, San Antonio, Texas
Most Popular Right Now
Online CME Activities
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.